Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Strikes Agreements With Roche Molecular, Eos Biotech


SANTA CLARA, Calif.--GeneChip developer Affymetrix here and Roche Molecular Systems announced a joint effort to develop and market a new generation of diagnostic tests that combines Affymetrix's GeneChip DNA probe array technology with Roche's PCR gene amplification technology. The companies will initially develop diagnostic kits for applications in HIV drug resistance. The agreement provides a framework for the development of additional GeneChip diagnostic kits as the parties identify further product opportunities.

Affymetrix also signed a series of agreements with Eos Biotechnology granting the South San Francisco startup access to custom and standard GeneChip expression arrays for application to Eos's molecular genomics research efforts in specific fields of cancer, inflammation, and cardiovascular disease. Eos will be able to purchase several thousand GeneChip probe arrays over the next 30 months. In exchange, Affymetrix will receive Series C preferred stock, gaining an ownership position in Eos of approximately 15 percent.

Filed under

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.